This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dr Li has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.
Researchers from The Netherlands recently evaluated the efficacy and safety of the bivalent HPV vaccine (Cervarix) administered at 0, 1, and 6 months in females aged 12 to 18 years with juvenile idiopathic arthritis [JIA] compared to healthy controls (HC).1 Immunogenicity was determined by measuring the level of HPV-specific IgG antibodies (reported as geometric mean concentration [GMC]) to calculate the seropositivity rate at 7 and 12 months after the first vaccination. Investigators also measured memory B cell responses before the first vaccination and 3, 7, and 12 months afterwards in a subset of JIA and …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.